Next Article in Journal
A 4-Year Retrospective Analysis of Salivary Gland Cytopathology Using the Milan System for Reporting Salivary Gland Cytology and Ancillary Studies
Next Article in Special Issue
SMYD3: An Oncogenic Driver Targeting Epigenetic Regulation and Signaling Pathways
Previous Article in Journal
Spatial EGFR Dynamics and Metastatic Phenotypes Modulated by Upregulated EphB2 and Src Pathways in Advanced Prostate Cancer
Previous Article in Special Issue
The Emerging Roles of ATP-Dependent Chromatin Remodeling Complexes in Pancreatic Cancer

Immunological Effects of Epigenetic Modifiers

by 1,2,3,4,5, 2,3,4,5, 3,4,5, 3,4,5,6,7,8,* and 3,4,5,*
Service anesthésie-réanimation, Hôpital européen Georges Pompidou, AP-HP, 75015 Paris, France
Faculty of Medicine, University of Paris Sud, 94270 Kremlin-Bicêtre, France
Equipe labellisée par la Ligue contre le cancer, 75000, Paris, France
Université de Paris, Sorbonne, INSERM U1138, Centre de Recherche des Cordeliers, 75006 Paris, France
Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, 94800 Villejuif, France
Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, 75015 Paris, France
Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, 215123 Suzhou, China
Department of Women’s and Children’s Health, Karolinska Institute, Karolinska University Hospital, 171 76 Stockholm, Sweden
Authors to whom correspondence should be addressed.
Cancers 2019, 11(12), 1911;
Received: 11 November 2019 / Revised: 27 November 2019 / Accepted: 28 November 2019 / Published: 1 December 2019
(This article belongs to the Special Issue Epigenetic Dysregulation in Cancer: From Mechanism to Therapy)
Epigenetic alterations are associated with major pathologies including cancer. Epigenetic dysregulation, such as aberrant histone acetylation, altered DNA methylation, or modified chromatin organization, contribute to oncogenesis by inactivating tumor suppressor genes and activating oncogenic pathways. Targeting epigenetic cancer hallmarks can be harnessed as an immunotherapeutic strategy, exemplified by the use of pharmacological inhibitors of DNA methyltransferases (DNMT) and histone deacetylases (HDAC) that can result in the release from the tumor of danger-associated molecular patterns (DAMPs) on one hand and can (re-)activate the expression of tumor-associated antigens on the other hand. This finding suggests that epigenetic modifiers and more specifically the DNA methylation status may change the interaction of chromatin with chaperon proteins including HMGB1, thereby contributing to the antitumor immune response. In this review, we detail how epigenetic modifiers can be used for stimulating therapeutically relevant anticancer immunity when used as stand-alone treatments or in combination with established immunotherapies. View Full-Text
Keywords: epigenetic modifiers; immunogenicity; cancer epigenetic modifiers; immunogenicity; cancer
Show Figures

Figure 1

MDPI and ACS Style

Bezu, L.; Wu Chuang, A.; Liu, P.; Kroemer, G.; Kepp, O. Immunological Effects of Epigenetic Modifiers. Cancers 2019, 11, 1911.

AMA Style

Bezu L, Wu Chuang A, Liu P, Kroemer G, Kepp O. Immunological Effects of Epigenetic Modifiers. Cancers. 2019; 11(12):1911.

Chicago/Turabian Style

Bezu, Lucillia, Alejandra Wu Chuang, Peng Liu, Guido Kroemer, and Oliver Kepp. 2019. "Immunological Effects of Epigenetic Modifiers" Cancers 11, no. 12: 1911.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop